NL-OMON36507已完成2 期
Guiding GC1008 treatment of primary brain tumors by 89Zr-GC1008 PET imaging. - GC1008 glioma
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 32
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. > 18 years
- •2. WHO 0,1,2
- •3. Patients with suspicion of malignant glioma on contrast-enhanced MRI within 4 weeks prior to enrolment.
- •4. Patients must be able to give written informed consent to participate. Patients may not be consented by a durable power of attorney.;Part II:
- •Patients with relapsed malignant glioma
- •Patient may have undergone surgery for the recurrence. If operated, residual and measurable disease after surgery is not required but surgery must have confirmed the recurrence. In case of operation, post-operative MRI must be made within 48 hours following surgery. Minimum interval of at least 4 weeks between surgery and the start of anti-TGF betha treatment, and patients should have fully recovered from the surgery. ;For non operated patients, recurrent disease must be at least one bidimensionally measurable target lesion (contrast enhancing lesion) with one diameter of at least 2cm, based on MRI scan done within 4 weeks prior to start of treatment. ;5. >18 years
- •6. WHO 0,1,2
- •7. Serum albumin >=3.0 g/dL.
- •8. Adequate organ function including :
- •a. Marrow: Hemoglobin >=10.0 g/dL, absolute neutrophil count (ANC) >=1,500/mm3, and platelets >=100,000/mm3.
- •b. Hepatic: Serum total bilirubin <=1.5 upper limit of normal (ULN) (Patients with Gilbert*s Disease may be included if their total bilirubin is <=3.0 mg/dL), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) <=2.5 x ULN.
- •c. Renal: Estimated or measured creatinine clearance >=60 mL/min.
- •d. Other: Prothrombin time (PT) and partial thromboplastin time (PTT) within normal ranges.
- •9. Patients must have negative tests (antibody and/or antigen) for hepatitis viruses B and C and human immunodeficiency virus (HIV), unless the result is consistent with prior vaccination or prior infection with full recovery.
- •10. At the time of enrollment, patients must be >4 weeks since major surgery, radiotherapy, chemotherapy (>=6 weeks if they were treated with a nitrosourea, mitomycin, or monoclonal antibodies such as bevacizumab), immunotherapy, or biotherapy/targeted therapies and recovered from the toxicity of prior treatment to <= Grade 1, exclusive of alopecia. Concurrent cancer therapy is not permitted (except for corticosterioids) . (In patients who received long acting agents, a treatment free interval of 2 half lives should be considered.)
- •11. Patients must be able to give written informed consent to participate. Patients may not be consented by a durable power of attorney.
- •12. Male and female patients of child-producing potential must agree to use effective contraception while enrolled on study and receiving the experimental drug, and for at least 3 months after the last treatment.
排除标准
- •1. Meningeal carcinomatosis, uncontrolled seizures, or a disease that either causes or threatens neurologic compromise (e.g., unstable vertebral metastases).
- •2. Pregnant or nursing women,:
- •3. A known allergy to any component of 89Zr-GC1008.
- •4. Patients who, in the opinion of the Investigator, have significant medical or psychosocial problems that warrant exclusion. Examples of significant problems include, but are not limited to:
- •a. Other serious non-malignancy-associated medical conditions that may be significantly increase the risk of SAEs.
- •b. Any condition, psychiatric, substance abuse, or otherwise, that, in the opinion of the Investigator, would preclude informed consent, consistent follow-up, or compliance;Part II:
- •5. History of ascites or pleural effusions , unless successfully treated, completely resolved, and the patient has not been treated for these conditions for >4 months.
- •6. Active thrombophlebitis, thromboembolism, hypercoagulability states, bleeding, or use of anti-coagulation therapy (including anti platelet agents such as aspirin, clopidogrel, ticlopidine, dipyridamole, and other agents used to induce long-acting platelet dysfunction). Patients with a history of deep venous thrombosis may participate if successfully treated, completely resolved, and no treatment has been given for >4 months.
- •7. Hypercalcemia: Calcium >11.0 mg/dL (2.75 mmol/L) unresponsive or uncontrolled in response to standard therapy (e.g., bisphosphonates).
- •8. Pregnant or nursing women, due to the unknown effects of GC1008 on the developing fetus or newborn infant.
- •9. Patients diagnosed with another malignancy - unless following curative intent therapy, the patient has been disease free for at least 5 years and the probability of recurrence of the prior malignancy is <5%. Patients with curatively treated early stage squamous cell carcinoma of the skin, basal cell carcinoma of the skin, or cervical intraepithelial neoplasia (CIN) are eligible for this study.
- •10. Patients with an organ transplant, including those that have received an allogeneic bone marrow transplant.
- •11. Use of investigational agents within 4 weeks prior to study enrollment (within 6 weeks if the treatment was with a long-acting agent such as a monoclonal antibody).
- •12. Patients on immunosuppressive therapy including: Patients receiving cyclosporine A, tacrolimus, or sirolimus are not eligible for this study.
- •13. Significant or uncontrolled medical illness, such as congestive heart failure (CHF), myocardial infarction, symptomatic coronary artery disease, significant ventricular arrhythmias within the last 6 months, or significant pulmonary dysfunction. Patients with a remote history of asthma or active mild asthma may participate.
- •14. Active infection, including unexplained fever (temperature >38.1 °C), or antibiotic therapy within 1 week prior to enrollment.
- •15. Systemic autoimmune disease (e.g., systemic lupus erythematosus, active rheumatoid arthritis, etc.).
- •16. A known allergy to any component of GC1008 or 89Zr-GC1008 .
- •17. Patients who, in the opinion of the Investigator, have significant medical or psychosocial problems that warrant exclusion. Examples of significant problems include, but are not limited to:
- •a. Other serious non-malignancy-associated medical conditions that may be expected to limit life expectancy or significantly increase the risk of SAEs.
- •b. Any condition, psychi
研究者
相似试验
进行中（未招募）
不适用
Treatment and imaging of primary brain tumorsHigh grade malignant gliomaEUCTR2010-021639-15-NLniversity Medical Center Groningen32
已完成
2 期
Safety and Imaging Study of GC1008 in GliomaPrimary Brain TumorsNCT01472731University Medical Center Groningen12
进行中（未招募）
不适用
First line standard therapy of glioblastoma multiforme with or without add-on treatment with Trivax, an anti-tumour immune therapy based on tumour-lysate charged dendritic cells - GBM-VaxPatients older than 3 years of age with newly diagnosed Glioblastoma Multiforme (GBM) undergoing brain surgery for removal of at least 70% of tumour mass and receiving subsequently standard radiation therapy and standard chemotherapy with temozolomide.MedDRA version: 14.1Level: PTClassification code 10018337Term: Glioblastoma multiformeSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-015979-27-ATActivartis Biotech GmbH76
进行中（未招募）
不适用
First Line Therapy of Glioblastoma Multiforme with Surgical Resection, Irradiation Therapy, Temozolomide and Additional Tumour-Lysate Pulsed Dendritic Cell Vaccination. A Feasibility Phase II Study. - NAGlioblastoma MultiformeEUCTR2009-013406-13-CZMasaryk University
招募中
不适用
Glioblastoma targeted treatment option maximization by WGS (GLOW);Maximizing treatment options for recurrent glioblastoma patients by whole genome sequencing-based diagnosticsGlioblstomamalignant brain tumor grade IV1002921110009720NL-OMON54315Haaglanden Medisch Centrum235